EUVIMEDEUVIMED entdecken
Crossref

Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer

Shintaro Yanazume iD, Chikako Nagata, Yusuke Kobayashi, Mika Fukuda, Mika Mizuno, Shinichi Togami iD, Hiroaki Kobayashi

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Shintaro Yanazume und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prognostic predictors of immunotherapy in patients with advanced endometrial cancer remain unclear. The potential role of inflammatory predictors, including pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and hemoglobin, albumin, lymphocyte and platelet scores, was investigated.

Methods

Between August 2018 and December 2023, 35 patients were retrospectively analyzed. Prognostic predictors were compared, and optimal cut-off values that exhibited the greatest discrimination for overall response, disease control, progression-free survival and overall survival were determined. Multivariate analysis was used to assess the prognostic significance of the predictors.

Results

The greatest discrimination for overall response, progression-free survival and overall survival included platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio and hemoglobin, albumin, lymphocyte and platelet; the areas under the curve were 0.638, 0.649 and 0.641, respectively. The precise cut-off values of neutrophil-to-lymphocyte ratio for progression-free survival and overall survival were 4.92 and 5.40, respectively. The lower neutrophil-to-lymphocyte ratio group had a significantly longer progression-free survival (P = 0.001, median survival; 4.0 months vs. 19 months) and longer overall survival (P = 0.002, median survival; 5.0 months vs. 21 months). Of the risk factors assessed, neutrophil-to-lymphocyte ratio (hazard ratio = 4.409; 95% CI = 1.10–17.64; P = 0.036) and regimen (hazard ratio = 5.559; 95% CI = 1.26–24.49; P = 0.023) were independently correlated with overall survival.

Conclusion

In patients with advanced endometrial cancer, pretreatment neutrophil-to-lymphocyte ratio may be a prognostic predictor of those who would benefit from immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsImmune Checkpoint InhibitorsHumansFemalePrognosisRetrospective StudiesMiddle AgedAgedNeutrophilsAdultAged, 80 and overLymphocytesProgression-Free Survival

Stichwörter der Autor:innen

endometrial cancerimmunotherapyneutrophil-to-lymphocyte ratiopembrolizumabprognosis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.

ORCID-Profile: Shintaro Yanazume, Shinichi Togami

Zitieren

APA

Yanazume, S., Nagata, C., Kobayashi, Y., Fukuda, M., Mizuno, M., Togami, S., & Kobayashi, H. (2025). Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae123

Vancouver

Yanazume S, Nagata C, Kobayashi Y, Fukuda M, Mizuno M, Togami S, et al. Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae123

BibTeX
@article{Yanazume2025,
  author = {Yanazume, Shintaro and Nagata, Chikako and Kobayashi, Yusuke and Fukuda, Mika and Mizuno, Mika and Togami, Shinichi and Kobayashi, Hiroaki},
  title = {Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae123}
}
Kostenlos starten →